Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Avacta Group plc ( (GB:AVCT) ).
Avacta Group plc has launched a £10 million equity fundraise via an accelerated placing of around 15 million new shares and a subscription for approximately 0.9 million shares at 63 pence, a 9.35% discount to the prior close. The proceeds are expected to extend the company’s cash runway into early Q1 2027 and support ongoing clinical development of its pre|CISION-based oncology pipeline, including the AVA6103 and faridoxorubicin programmes.
The funding will help advance AVA6103, a pre|CISION peptide drug conjugate based on exatecan, through its Phase 1a trial with initial data expected in late 2026, while also backing Phase 1b expansion cohorts of faridoxorubicin across multiple tumour types. Directors Richard Hughes and David Bryant intend to invest about £550,000 combined, signalling internal confidence as Avacta seeks to retain full rights to AVA6103 ahead of key data readouts and continues discussions with potential partners for its lead assets.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £48.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on AVCT Stock
According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on AVCT stock, click here.
More about Avacta Group plc
Avacta Group plc is a clinical-stage biopharmaceutical company focused on oncology, developing its proprietary pre|CISION tumour-activated drug delivery platform. The company engineers peptide drug conjugates that aim to deliver highly potent cancer therapies directly to tumours while reducing systemic toxicity, targeting indications such as salivary gland cancer, triple negative breast cancer and soft tissue sarcoma.
Average Trading Volume: 1,647,710
Technical Sentiment Signal: Buy
Current Market Cap: £304M
For an in-depth examination of AVCT stock, go to TipRanks’ Overview page.